Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| enzymes | 5718 | None |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Velmanase alfa-tycv provides an exogenous source of alpha-mannosidase. Velmanase alfa-tycv is internalized via binding to the mannose-6-phosphate receptor on the cell surface and transported into lysosomes where it is thought to exert enzyme activity. Alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in Mannosidase Alpha Class 2B Member 1. Alpha-mannosidase catalyzes the degradation of accumulated mannose-containing oligosaccharides. The deficiency of alpha-mannosidase causes an intra-lysosomal accumulation of mannose-rich oligosaccharides in various tissues.
|
| Dose | Unit | Route |
|---|---|---|
| 10 | mg | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 16, 2023 | FDA | CHIESI FARMACEUTICI SPA | |
| March 23, 2018 | EMA | CHIESI FARMACEUTICI SPA |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | A16AB15 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Enzymes |
| FDA CS | M0085930 | alpha-Mannosidase |
| FDA EPC | N0000194082 | Recombinant Human Lysosomal alpha-Mannosidase |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Alpha-mannosidosis | indication | 65524005 |
None
None
None
None
None
None
| ID | Source |
|---|---|
| DB12374 | DRUGBANK_ID |
| 1012851000202107 | SNOMEDCT_US |
| 4042060 | VANDF |
| 4042061 | VANDF |
| C5789771 | UMLSCUI |
| CHEBI:757435 | CHEBI |
| CHEMBL4298010 | ChEMBL_ID |
| 1492823-75-2 | SECONDARY_CAS_RN |
| 32051 | PUBCHEM_CID |
| 365238 | MMSL |
| 41253 | MMSL |
| d10006 | MMSL |
| 018239 | NDDF |
| D11024 | KEGG_DRUG |
| 10140 | INN_ID |
| 2630724 | RXNORM |
| C000731931 | MESH_SUPPLEMENTAL_RECORD_UI |
| M91TG242P2 | UNII |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Lamzede | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10122-180 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 10 mg | INTRAVENOUS | BLA | 26 sections |